APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

26 Jan 2024 06:06:23 By Nasdaq GlobeNewswire

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

08 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

28 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

14 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

11 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

21 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

04 Nov 2023 12:37:55 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

01 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

25 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

20 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

17 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

05 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

02 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

25 Sep 2023 06:30:00 By Nasdaq GlobeNewswire